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placed): 0.929(0.712); (undisplaced/displaced): 0.847(0.249); Comorbidities (no/yes):
0.963(0.836); Surgical types (arthroplasty/osteosynthesis): 1.405(0.026); Antiosteo-
porotic treatment (2years/none): 0.512(0.006); (2years/none): 0.529 (0.004).
CONCLUSIONS: The risk of second hip fracture in elderly 8 year follow up period
was the highest in female, in older age-group, in patient after arthroplasty and in
patient without pharmacologic treatment for osteoporosis. The effect of single risk
factors on the risk of subsequent hip fractures should be investigated in the future.
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OBJECTIVES: To perform a systematic review of prospective observational studies
in patients with RA to examine the safety of TNF-I in daily practice, with particular
focus on malignancy, and serious and opportunistic infections. METHODS: Com-
prehensive searches of Medline, Embase, the Cochrane Database of Systematic
Reviews, and ACR, EULAR and BSR conference abstracts were performed according
to a pre-specified protocol that excluded randomised controlled trials. Type and
site of malignancies, as well as serious and opportunistic infections, such as tuber-
culosis, were extracted. Publications that reported incidence rates, standardised
incidence ratios or measures of relative risk, such as incidence rate ratios, odds
ratios or hazard ratios, were selected for random effects meta-analyses. RESULTS:
A total of 2039 papers and 1979 abstracts were identified, of which 48 and 21 re-
spectively met the pre-specified inclusion criteria. The pooled estimate for the
relative risk (RR) of overall malignancy from seven studies was 0.94 (95% CI 0.84,
1.05; I2  0.0%). In contrast, the meta-analysis of serious infections had much
higher heterogeneity, I2 40.9%, RR 1.34 (95% CI 1.06, 1.62). CONCLUSIONS: This
review included data from European, US and Japanese studies with 130,000 pa-
tient years of exposure. Data from such a large number of patients, often with
extended follow-up, overcomes the weaknesses of clinical trial data, specifically
fewer patient numbers and usually shorter exposure times. Observational data has
known weaknesses related to non-randomisation such that statistical techniques
have to be used to overcome differences between the exposed and reference co-
horts. Despite such confounding factors, consideration of the available evidence
leads to the conclusion that there is an increased risk of serious and opportunistic
infections with TNF-I, although no evidence of increased the risk of malignancy.
Meta-analyses of randomised controlled trials have come to different conclusions
regarding both the risk of infections and of malignancy.
Muscular-Skeletal Disorders – Cost Studies
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A BUDGET IMPACT MODEL FOR THE USE OF ABATACEPT AS A FIRST BIOLOGIC
TREATMENT FOR RHEUMATOID ARTHRITIS IN ITALY
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OBJECTIVES:Objective of the study was the budget impact analysis (BIA) of the use
of abatacept as first biologic line for rheumatoid arthritis (RA) patients in Italy.
METHODS: The BIA was based on a Markov model with 6-months cycles and
3-years time horizon. The target population, formed by RA patients starting a first
biologic treatment, was estimated based on RA prevalence and market share data
for biologic drugs. The sequence including abatacept (ABA) as first line was com-
pared with two more traditional sequences of anti-TNF (IFXinfliximab;
ETNetanercept; ADAadalimumab) and rituximab (RTX). The compared se-
quences were: ABA-IFX-RTX; ETN-IFX-RTX; ADA-IFX-RTX. The switch between
treatments for intolerance, adverse events or lack of efficacy was simulated on the
basis of data from RCTs. The disease progression was classified with the ACR
(American College of Rheumatology) I, II, III and IV functional states. Treatments
efficacy was obtained from published RCTs as average reduction of the Health
Assessment Questionnaire (HAQ) score. The HAQ score was then correlated with
the ACR states. Direct costs were valued in the perspective of the Italian health care
system and classified in purchasing, administration and patients routine manage-
ment (visits, exams, hospital stay and other drugs). RESULTS: Italian target popu-
lation was estimated in about 7000 RA patients. At the end of the third year patients
still on first biologic drug were 5670, 4610, and 4680 in the sequence with ABA, ETN
and ADA. Patients in ACR I or II were 6240, 6160 and 6000 respectively. The annual
cost at the third year was €47.0 million, €48.5 million and €47.8 million for the
sequence with ABA, ETN and ADA respectively. CONCLUSIONS: The use of ABA as
first biologic line treatment for RA showed to provide better control of the disease
along with a positive impact in total costs, when compared with traditional se-
quences based on anti-TNF in Italy.
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OBJECTIVES: Data about the burden of JIA are necessary to allocate health care
resources. METHODS: Records were examined for 6 months retrospectively. Bur-
den of JIA in Russia was gotten by summarizing direct and indirect medical costs of
all patients with JIA. The total number of JIA patients and annualized costs were
calculated based on extrapolation method. RESULTS: Data on 405 patients were
obtained. Group with biologics included 124 patients(30.6%), without biologics –
269(66.4%), data about 9(3%) persons were absent. Among 6 biologics used in Russia
for JIA treatment (Abatacept, Adalimumab, Etanercept, Infliximab, Rituximab and
Tocilizumab), costs of biologics and total costs per patient were the smallest in case
of Etanercept – 5,131 USD and 6,967 USD and the biggest with Rituximab - 19,530
USD and 21,944 USD. One-year direct costs per patient with biologics were 36,065
USD. One-year direct costs per patient without biologics was 3149 USD. Average
one-year indirect costs were the same for patients with and without biologics -
1442 USD. Total number of patients with JIA in 2010 was 18,626 people, only 930(5%)
(data of National Center for Child Health of Russian Academy of Medical Sciences,
Moscow, Russia) received biologics. One-year direct costs of all patients with JIA -
89,491,976 USD; indirect costs - 27,491,976 USD; the burden of JIA -116,754,031 USD.
CONCLUSIONS: In 2010 total number of patients with JIA in Russia was estimates
as 18,626 people; burden of JIA was 116,754,031 USD.
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COST OF ETANERCEPT, ADALIMUMAB, AND INFLIXIMAB PER TREATED
PATIENT ACROSS ADULT INDICATIONS USING REAL-WORLD DATA
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OBJECTIVES: To estimate the annual cost of etanercept, adalimumab and inflix-
imab per treated patient across adult indications using drug utilization from a US
managed care population.METHODS:MarketScan Commercial Database was used
to identify all adult patients (18-64 years) with 1 claim for etanercept, adali-
mumab, or infliximab between November 1, 2005-June 6, 2009 who were biologic-
naïve or continuing TNF-blocker treatment (i.e., received a TNF-blocker before the
first (index) claim in the study period) and had a diagnosis for rheumatoid arthritis,
psoriasis, psoriatic arthritis, or ankylosing spondylitis. Patients were required to be
continuously enrolled for 6-months pre-index and 1-year following the index
claim. Patients with Crohn’s disease, or ulcerative colitis in the pre-index period
were excluded. Mean monthly dose was calculated for the 3 TNF-blockers for a
12-month period while patients were on therapy. Wholesale acquisition costs and
the Medicare Physician Fee Schedule were applied to the mean monthly dose and
related drug administration to estimate TNF-blocker cost per treated patient.
RESULTS: Overall, 12,065 etanercept, 5,685 adalimumab, and 3,902 infliximab pa-
tients were included. Biologic-naïve patients consisted of 43% of patients. Patient
characteristics were similar across treatment groups with a mean age (SD) of 49 (10)
years and 66% female. The mean annual TNF-blocker cost per treated patient for all
patients was $14,446 for etanercept, $18,000 for adalimumab, and $23,348 for inf-
liximab. In biologic-naïve patients, the TNF-blocker cost per treated patient was
$13,703 for etanercept, $16,932 for adalimumab, and $20,500 for infliximab; in pa-
tients continuing treatment it was $14,901 for etanercept, $19,410 for adalimumab,
and $25,028 for infliximab. CONCLUSIONS: Patients receiving etanercept had the
lowest TNF-blocker cost per treated patient for adult indications when using actual
drug utilization from a US managed care population. TNF-blocker costs per treated
patient on adalimumab and infliximab, respectively are approximately 25% and
62% higher than etanercept.
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OBJECTIVES: To describe annual costs of etanercept, adalimumab and infliximab
per treated patient across adult indications using real-world US drug data.
METHODS: IMS LifeLink™ Health Plan Claims database was used to identify adult
patients (18y) with 1 claim for etanercept, adalimumab or infliximab between
January 1, 2005-March 31, 2009 (first TNF-blocker claim in study period is index
claim); patients who were biologic-naïve or continuing TNF-blocker treatment
were included. Patients had to have 360 days continuous enrollment following
index claim and 180 days prior to index claim (pre-index period). In the pre-index
period, patients were included if they had a diagnosis of rheumatoid arthritis,
psoriasis, psoriatic arthritis, or ankylosing spondylitis, but were excluded if they
had a diagnosis of Crohn’s disease or ulcerative colitis. Patients were followed for
1-year. Mean monthly dose was computed for patients on therapy; wholesale ac-
quisition costs were applied to mean monthly dose and Medicare Physician Fee
Schedule was applied to related drug administrations. Costs from restarting index
TNF-blocker therapy after discontinuation and costs from switching to a different
TNF-blocker were attributed to patients’ index therapy. RESULTS: Overall, 27,704
patients (14,777 etanercept, 6,862 adalimumab, 6,065 infliximab), were identified.
The indication mix was 65% rheumatoid arthritis, 11% psoriasis, 13% psoriatic
arthritis, 5% ankylosing spondylitis, and 6% with multiple indications. The 1-year
mean cost per treated patient for all patients was lowest for etanercept, $14,013,
followed by adalimumab, $17,716, then infliximab, $20,665. For biologic-naïve pa-
tients, mean cost per treated patient was $13,342 for etanercept, $16,718 adali-
mumab, and $18,589 infliximab. For patients continuing biologic therapy, cost per
treated patient was $14,438 for etanercept, $18,816 adalimumab, and $21,846
infliximab. CONCLUSIONS: When comparing TNF-blocker cost per treated patient
across adult indications, etanercept has the lowest cost per treated patient com-
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pared to adalimumab and infliximab when using actual drug utilization data from
US commercially-insured population.
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POTENTIAL COST SAVING OF EPOETIN ALFA COMPARED TO AUTOLOGOUS
BLOOD DONATION OR TO NO-BLOOD-CONSERVATION-STRATEGY BEFORE
ELECTIVE HIP OR KNEE SURGERY DUE TO REDUCTION IN ALLOGENEIC BLOOD
TRANSFUSIONS AND ITS SIDE EFFECTS
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OBJECTIVES: Transfusion of allogeneic blood still is common in orthopedic surgery
albeit associated with higher morbidity and mortality. This analysis evaluates from
the perspective of a German hospital the potential cost savings of Epoetin alfa
compared to predonated autologous blood transfusions or to no-blood-conserva-
tion-strategy during elective hip and knee replacement surgery by reducing allo-
geneic blood transfusions and their associated infectious adverse events.
METHODS: Individual patients (n  10,000) were created based on data from con-
trolled trials, the German DRG institute (InEK) and various publications and entered
into a stochastic model (Monte-Carlo) one of three treatment arms: Epoetin alfa,
preoperative autologous donation and no-blood-conservation-strategy. The model
is focused on the costs and events of the procedure and follow-up. The model was
validated by an independent external consultant. Clinical and economical vari-
ables were obtained from clinical trial databases, the German DRG System, patient
records and medical publications- in particular cost per transfusion (allogeneic red
blood cells: € 320/unit and autologous red blood cells: € 280/unit), pneumonia treat-
ment (€ 5,000), and length of stay (€ 300/day). Probabilistic sensitivity analyses were
performed to determine which, if any, factors had an influence on the model’s
clinical and cost outcomes. RESULTS:At acquisition costs of € 375/40,000 IE Epoetin
alfa is cost saving compared to autologous blood donation, and at € 185/40,000 IE
compared to no-blood-conservation-strategy. The results were most sensitive to
the cost of Epoetin alfa, blood units and hospital days. CONCLUSIONS: Upcoming
shortages and increasing prices of red blood cells will make Epoetin alfa an attrac-
tive blood conservation strategy for anemic patients at reasonable costs, due the
reduction in allogeneic blood transfusions and their associated infectious adverse
events.
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THE EFFECT OF BIOLOGICAL TREATMENT ON WORK PRODUCTIVITY AND
PRODUCTIVITY COSTS OF RHEUMATOID ARTHRITIS PATIENTS
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OBJECTIVES: Biologics represent significant costs of rheumatic diseases treatment.
Our study has focused on productivity comparison of rheumatoid arthritis (RA)
patients treated with biologics and patients on DMARDs who are indicated to bio-
logic treatment however therapy is unavailable due to economic limitations.
METHODS: Work Productivity and Activity Impairment Questionnaire (WPAI:RA)
was administered to two groups of patients - patients treated with biologics (n76)
with low disease activity and patients just on DMARDs (n23) with high disease
activity (DAS28 score  5,1). All patients were in productive age. Patients’ demo-
graphics, clinical and PRO parameters (DAS28, HAQ, time from diagnosis) and
working statuses we collected by rheumatologist. Productivity costs were calcu-
lated by friction cost approach using friction period of 130 work-days and average
monthly gross income as denominator. RESULTS: Mean patients= age on biologics
and on DMARDs were 41.0 years (21-61) and 45.7 (22 – 61), respectively. Mean time
from diagnosis of biologics and DMARDs groups were 13.5 and 11.6 years, respec-
tively. Average HAQ and DAS28 were 0.77 and 2.64, respectively for patients on
biologics and 1.14, 5.62, respectively for patients on DMARDs. Patients on biologics
were slightly more work-disable (26.3%) compare to 25.0% DMARDs patients. Over-
all work-impairment (for patients that reported any work-impairment) for patients
on biologics and for patients on DMARDs was 28.1% and 49.6%, respectively. Pa-
tients on biologics reported less reduction of daily activities (39.8%) in compare to
patients on DMARDs (50.5%). Average annual productivity costs per one patient on
biologics and for DMARDs patient were € 1802 and € 2769, respectively.
CONCLUSIONS: Despite of the fact, patients on biologics had longer time from
diagnoses, they reported significantly lower work-impairment and reduction of
daily activities in compare to DMARDs patients, which reflected about 53.6% higher
productivity costs for patients on DMARDs. Biologic treatment preserves produc-
tivity and save productivity costs.
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OBJECTIVES: International pharmacoeconomic studies suggest Health Assess-
ment Questionnaire (HAQ) as an important predictor of evaluation both direct and
productivity costs. Costs are supposed to increase with increasing HAQ score.
Therefore, we calculated direct and productivity costs for five groups of patients
according to their HAQ (0.6, 0.6-1.1, 1.1-1.6, 1.6-2.1, 2.1) to confirm this assump-
tion also in the Czech Republic. METHODS: This calculation was based on a retro-
spective cross-sectional study. We included 126 patients with rheumatoid arthritis,
aged 18-84 years either at working status, part-time disabled or full-time disabled.
For estimation of direct medical costs, we used microcosting method retrospec-
tively reviewing individual patients’ medical records. For calculation of productiv-
ity costs we excluded patients older than 63 years of age (retirement pensioners).
We used friction costs approach (FCA) with defined friction period of 130 workdays,
based on patients’ absenteeism. Productivity of part-time-disabled and full-time
disabled patients were assumed to be deteriorated by 52% and 70%, respectively,
based on the Czech law on pension insurance. The height of average monthly
income in year 2010, €960.3 was used as denominator. Costs were expressed as
mean value per one patient with RA in each of the HAQ-group. RESULTS: Average
patients= age was 57.3 years; average time from diagnosis was 17.5 years with mean
HAQ score 1.4 and mean DAS28 3.62. Mean annual medical direct costs, for each
HAQ-group, were €4076.7, €5950.2, €4691.3, €6932.1, and €6727.1, respectively. Mean
annual indirect costs associated with productivity loss were €481.5, €1178.6,
€1267.7, €1585.6, and €2122.5, respectively. CONCLUSIONS: Direct and productivity
costs for patients with rheumatoid arthritis are closely related to the height of HAQ
score. Total (direct and productivity) annual mean costs were €7135.6. 31.0% of all
patients were treated with biological treatment which represented up to 79.4% of
the overall direct medical costs.
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OBJECTIVES: To determine the healthcare resource use (HRU) and costs attribut-
able to osteoporosis and osteoporosis-related fractures in post-menopausal
women in Greece METHODS: A multi-point data collection procedure, based on
strictly-structured interviews with 137 geographically distributed physicians, was
used to construct and populate the disease management model for women with
post-menopausal osteoporosis (PMO) aged 50years. The model was further vali-
dated by a group of 12 experts. Secondly, all HRU items in the model were costed in
order to provide per-patient costs of treatment. Cost variables included costs of
consultations, laboratory tests, osteoporotic medication, dietary supplements,
hospitalization due to fractures and rehabilitation, allcalculated from a third-party
payer perspective (Euros, 2011) for a 1year timeframe (retrospective).RESULTS:The
mean annual cost per PMO patient was €1,384.67 (95%CI: 423.27 – 7281.16). When
distinguishing between women with established (PMO with a previous fracture)
(27.6% of total) and non-established PMO, the mean annual cost per patient was
€2027.46 (95%CI: 508.09-7241.90) and €1139.63 (95%CI: 461.86 - 1324.44) respectively.
For PMO women with an established osteoporosis for1year the mean annual cost
was significantly higher compared to those with an established osteoporosis for 
1year €2714.98 (95%CI: 820.17 – 7284.42) versus €1805.54 (95%CI: 508.09 – 7241.77).
The mean annual cost per patient with a fracture was €4,334.27 (95%CI: 1,452.86 –
10,730.17) for a hip, €2,723.27 (95%CI: 1,470.39 – 7,839.55) for a vertebral and
€1,731.35 (95%CI: 1,131.17 - 1,942.48) for a Colles fracture respectively. The sensi-
tivity analysis (10% change of baseline values) showed that the factors with the
greatest impact on total cost were the probability of established osteoporosis, the
probability of a fracture in the previous 12 months, cost of parathormone treatment
and the cost of patient monitoring. CONCLUSIONS: Treatment of osteoporosis is
costly. Efforts to control the main osteoporosis cost drivers and hence its economic
impact on the health care budgets, are necessary.
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OBJECTIVES: Psoriasis (prevalence 2-3%) is not directly life-threatening disease.
However, patients suffering from psoriasis and psoriatic arthritis (PsA) are experi-
encing lower quality of life. Treatment of these diseases represents a significant
financial burden for the healthcare system. METHODS: Study was based on 12-
months retrospective electronic questionnaire reported by dermatologist. We used
societal perspective using friction cost approach method for productivity costs
calculation. Patients’ demographics, clinical data (PASI and BSA index), direct costs
(inpatient/outpatient care, local/systemic treatment etc.), productivity costs (inva-
lidity, sick leave) and on QoL (EQ-5D, DLQI) were collected. RESULTS: A total of 256
patients participated in the study, average patients= age was 46.79 years (9-75
years), average time from diagnosis was 25.52 years with average PASI 13,76, BSA
28,09%, DLQI 11,74 and EQ-5D 0,7633. Occurrence of PsA was 34.4%. Major direct
costs driver was phototherapy (47% of direct costs), systematic treatment (17%) and
inpatient care (15%). Within the productive-age patients (18-63 years), 8.6% of pa-
tients were fully disabled, 7.4% partially disabled, 73% patients were work-active,
and 11% were unemployed, retired or students. 17.2% of work-active patients re-
ported incapacity to work with average duration of 33 days in previous 6 months.
Mean indirect costs associated with productivity loss were €848.3 per work-active
patient per year €1343.0 per work-active patient with PsA. Mean annual costs per
patient with moderate to severe psoriasis and/or PsA were calculated to €3736.5
(direct costs 77%, €2888.2). Mean annual costs per patient with PsA were €4328.3
including €2985.3 for direct costs (69%). CONCLUSIONS: Direct costs remain major
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